IPF is a life-threatening lung disease with no known cause. Over time, the lungs become scarred, making it harder to breathe. More than 250,000 Americans are living with IPF and other interstitial ...

IPF study will evaluate efficacy of two doses of LYT-100, one with comparable exposure to FDA-approved dose of pirfenidone and one with higher exposure, vs. placebo, as well as relative tolerability ...

Achieving equitable access to anti-fibrotic drugs requires multi-stakeholder collaboration, while the most critical unmet ...

SAN DIEGO -- Two novel drugs improved lung function in idiopathic pulmonary fibrosis (IPF) in a pair of phase IIa trials, researchers reported here. In an open-label, single-arm trial of 46 patients ...

Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.

Dublin, March 28, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis, 2016" report to their offering. The IPF ...

Tazarotene demonstrated promising efficacy and safety in a mid-stage study, meeting primary and secondary endpoints.

Of 14 metabolites identified, 2 appeared to have “robust” causal relationships with idiopathic pulmonary fibrosis. Fourteen metabolites appeared to have a causal relationship with idiopathic pulmonary ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...